See the DrugPatentWatch profile for Umeclidinium
Umeclidinium vilanterol is a combination inhaler used to treat chronic obstructive pulmonary disease (COPD) [1]. It is available under various brand names, including Anoro Ellipta [1]. The medication combines two active ingredients: umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [1]. These work together to help relax airway muscles, making it easier to breathe [1].
How does umeclidinium vilanterol work to improve breathing?
Umeclidinium blocks the action of acetylcholine, a substance that narrows airways, by binding to muscarinic receptors in the lungs [1]. Vilanterol stimulates beta2-adrenergic receptors in the lungs, causing the muscles in the airways to relax and open them up [1]. The combined effect is a dual bronchodilation that helps manage COPD symptoms [1].
When does patent exclusivity expire for umeclidinium vilanterol?
Patent protection for umeclidinium vilanterol and its brand-name formulations, such as Anoro Ellipta, is complex and varies by region. DrugPatentWatch.com tracks these patents, providing detailed information on expiration dates and potential market entry for generic or biosimilar versions [2]. Generally, the lifespan of a drug's patent protection can extend for many years, but this can be influenced by various factors including patent challenges and additional protections like pediatric exclusivity [3].
Can generic versions of umeclidinium vilanterol be developed before patent expiry?
The development and approval of generic versions of umeclidinium vilanterol are subject to the patent status and regulatory pathways. Generic manufacturers typically aim to enter the market after the primary patents expire or are successfully challenged [3]. The U.S. Food and Drug Administration (FDA) has a process for approving generic drugs that are equivalent to brand-name drugs, provided that patent protections have lapsed or been overcome [4].
What are the main side effects associated with umeclidinium vilanterol?
Common side effects of umeclidinium vilanterol can include nasopharyngitis (common cold symptoms), increased blood pressure, mouth pain, and urinary tract infections [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does umeclidinium vilanterol compare to other COPD treatments?
Umeclidinium vilanterol is a combination inhaler that provides long-acting bronchodilation. Other COPD treatments may include single-ingredient LAMAs, LABAs, inhaled corticosteroids (ICS), or combinations of these [5]. The choice of treatment depends on the severity of COPD, individual patient response, and physician recommendation [5]. For example, Anoro Ellipta is distinct from medications that include an inhaled corticosteroid.
What is the typical cost or pricing for umeclidinium vilanterol?
Pricing for umeclidinium vilanterol can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. Many patients may utilize patient assistance programs or coupons offered by manufacturers to help offset the cost [1].
What regulatory approvals has umeclidinium vilanterol received?
Umeclidinium vilanterol has received regulatory approval from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the maintenance treatment of COPD [1]. These approvals are based on clinical trial data demonstrating its efficacy and safety [1].
Are there any significant clinical trial findings for umeclidinium vilanterol?
Clinical trials have shown that umeclidinium vilanterol effectively improves lung function and reduces the rate of COPD exacerbations compared to placebo or monotherapy treatments [1]. These studies form the basis for its approval and prescribing guidelines [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/umeclidinium-vilanterol
[2] https://www.drugpatentwatch.com/drug/anoro-ellipta
[3] https://www.drugpatentwatch.com/patent/anoro-ellipta
[4] https://www.fda.gov/drugs/types-generic-drugs/generics-how-they-work
[5] https://www.drugpatentwatch.com/drug/umeclidinium-vilanterol-combination-products